Which has higher valuation & earnings, TTRX or SLDB?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A Solid Biosciences N/A N/A -$174.32M -$1.95 N/A

Is TTRX or SLDB more profitable?

Turn Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A N/A N/A Solid Biosciences N/A -73.42% -61.13%

Does the media refer more to TTRX or SLDB?

In the previous week, Turn Therapeutics had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 2 mentions for Turn Therapeutics and 1 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.08 beat Turn Therapeutics' score of -0.36 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Solid Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TTRX or OCS?

In the previous week, Oculis had 1 more articles in the media than Turn Therapeutics. MarketBeat recorded 3 mentions for Oculis and 2 mentions for Turn Therapeutics. Oculis' average media sentiment score of 0.00 beat Turn Therapeutics' score of -0.36 indicating that Oculis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Oculis 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation & earnings, AURA or TTRX?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A

Is AURA or TTRX more profitable?

Turn Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Turn Therapeutics N/A N/A N/A

Does the media refer more to AURA or TTRX?

In the previous week, Aura Biosciences and Aura Biosciences both had 2 articles in the media. Aura Biosciences' average media sentiment score of 0.03 beat Turn Therapeutics' score of -0.36 indicating that Aura Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, TTRX or CLYM?

Turn Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Turn Therapeutics N/A N/A -$3.19M -$0.19 N/A Climb Bio N/A N/A -$59.85M -$0.78 N/A

Is TTRX or CLYM more profitable?

Turn Therapeutics' return on equity of 0.00% beat Climb Bio's return on equity. Company Net Margins Return on Equity Return on Assets Turn Therapeutics N/A N/A N/A Climb Bio N/A -31.45% -30.39%

Is ALLO or TTRX more profitable?

Turn Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Allogene Therapeutics N/A -56.45% -40.36% Turn Therapeutics N/A N/A N/A

Does the media refer more to ALLO or TTRX?

In the previous week, Turn Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 2 mentions for Turn Therapeutics and 1 mentions for Allogene Therapeutics. Turn Therapeutics' average media sentiment score of -0.36 beat Allogene Therapeutics' score of -1.74 indicating that Turn Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Very Negative Turn Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Turn Therapeutics (TTRX) Competitors

$5.77 -0.10 (-1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$5.72 -0.05 (-0.87%)

As of 05:01 PM Eastern

Compare

TTRX vs. SLDB, OCS, AURA, CLYM, and ALLO

Should you buy Turn Therapeutics stock or one of its competitors? MarketBeat compares Turn Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Turn Therapeutics include Solid Biosciences (SLDB), Oculis (OCS), Aura Biosciences (AURA), Climb Bio (CLYM), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry.

How does Turn Therapeutics compare to Solid Biosciences?

Turn Therapeutics (NASDAQ:TTRX) and Solid Biosciences (NASDAQ:SLDB) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, institutional ownership, profitability, dividends and analyst recommendations.

In the previous week, Turn Therapeutics had 1 more articles in the media than Solid Biosciences. MarketBeat recorded 2 mentions for Turn Therapeutics and 1 mentions for Solid Biosciences. Solid Biosciences' average media sentiment score of 1.08 beat Turn Therapeutics' score of -0.36 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Solid Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Turn Therapeutics' return on equity of 0.00% beat Solid Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Solid Biosciences	N/A	-73.42%	-61.13%

Turn Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

81.5% of Solid Biosciences shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Turn Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 38.65%. Solid Biosciences has a consensus price target of $17.00, suggesting a potential upside of 104.82%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Solid Biosciences beats Turn Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Turn Therapeutics compare to Oculis?

Turn Therapeutics (NASDAQ:TTRX) and Oculis (NASDAQ:OCS) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Turn Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 38.65%. Oculis has a consensus target price of $38.33, indicating a potential upside of 228.48%. Given Oculis' stronger consensus rating and higher possible upside, analysts plainly believe Oculis is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Turn Therapeutics has higher earnings, but lower revenue than Oculis. Turn Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Oculis	$1.45M	466.64	-$119.44M	-$2.13	N/A

22.3% of Oculis shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Turn Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,460.67%. Turn Therapeutics' return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Oculis	-8,460.67%	-56.78%	-45.62%

In the previous week, Oculis had 1 more articles in the media than Turn Therapeutics. MarketBeat recorded 3 mentions for Oculis and 2 mentions for Turn Therapeutics. Oculis' average media sentiment score of 0.00 beat Turn Therapeutics' score of -0.36 indicating that Oculis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oculis	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oculis beats Turn Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Turn Therapeutics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Turn Therapeutics is trading at a lower price-to-earnings ratio than Aura Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

96.8% of Aura Biosciences shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Turn Therapeutics' return on equity of 0.00% beat Aura Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Turn Therapeutics	N/A	N/A	N/A

Aura Biosciences presently has a consensus price target of $20.50, suggesting a potential upside of 194.96%. Turn Therapeutics has a consensus price target of $8.00, suggesting a potential upside of 38.65%. Given Aura Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Aura Biosciences is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Aura Biosciences and Aura Biosciences both had 2 articles in the media. Aura Biosciences' average media sentiment score of 0.03 beat Turn Therapeutics' score of -0.36 indicating that Aura Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aura Biosciences beats Turn Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Turn Therapeutics compare to Climb Bio?

Turn Therapeutics (NASDAQ:TTRX) and Climb Bio (NASDAQ:CLYM) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, valuation, profitability, risk, dividends, earnings and analyst recommendations.

In the previous week, Turn Therapeutics had 2 more articles in the media than Climb Bio. MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for Climb Bio. Climb Bio's average media sentiment score of 0.00 beat Turn Therapeutics' score of -0.36 indicating that Climb Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Turn Therapeutics	Neutral
Climb Bio	Neutral

69.8% of Climb Bio shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Turn Therapeutics' return on equity of 0.00% beat Climb Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Turn Therapeutics	N/A	N/A	N/A
Climb Bio	N/A	-31.45%	-30.39%

Turn Therapeutics is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A

Turn Therapeutics presently has a consensus target price of $8.00, indicating a potential upside of 38.65%. Climb Bio has a consensus target price of $21.73, indicating a potential upside of 78.38%. Given Climb Bio's stronger consensus rating and higher probable upside, analysts clearly believe Climb Bio is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07

Summary

Climb Bio beats Turn Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Turn Therapeutics compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

83.6% of Allogene Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Turn Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 2 mentions for Turn Therapeutics and 1 mentions for Allogene Therapeutics. Turn Therapeutics' average media sentiment score of -0.36 beat Allogene Therapeutics' score of -1.74 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Very Negative
Turn Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Turn Therapeutics has lower revenue, but higher earnings than Allogene Therapeutics. Turn Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	36,240.75	-$190.89M	-$0.77	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.19	N/A

Turn Therapeutics' return on equity of 0.00% beat Allogene Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Turn Therapeutics	N/A	N/A	N/A

Allogene Therapeutics currently has a consensus target price of $8.52, suggesting a potential upside of 305.82%. Turn Therapeutics has a consensus target price of $8.00, suggesting a potential upside of 38.65%. Given Allogene Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Allogene Therapeutics is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Turn Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Allogene Therapeutics beats Turn Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Turn Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TTRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TTRX vs. The Competition

Export

Metric	Turn Therapeutics	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$171.88M	$913.07M	$4.40B	$12.38B
Dividend Yield	N/A	4.84%	10.94%	5.81%
P/E Ratio	-30.37	1.41	22.10	24.35
Price / Sales	N/A	122.14	157.99	128.85
Price / Cash	N/A	20.06	41.09	37.84
Price / Book	36.06	7.73	18.40	6.58
Net Income	-$3.19M	-$5.20M	$115.37M	$336.75M
7 Day Performance	-10.12%	-0.18%	-0.48%	-0.49%
1 Month Performance	12.48%	1.11%	-0.93%	1.56%
1 Year Performance	N/A	50.43%	14.52%	33.78%

Turn Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TTRX Turn Therapeutics	2.427 of 5 stars	$5.77 -1.7%	$8.00 +38.6%	N/A	$171.88M	N/A	N/A	2	Gap Down
SLDB Solid Biosciences	2.8421 of 5 stars	$7.22 +9.2%	$17.00 +135.5%	+73.9%	$650.75M	N/A	N/A	100	High Trading Volume
OCS Oculis	2.8395 of 5 stars	$11.00 +0.3%	$38.33 +248.5%	-41.8%	$636.09M	$1.45M	N/A	2
AURA Aura Biosciences	2.5632 of 5 stars	$6.21 +1.5%	$20.50 +230.1%	+5.0%	$632.73M	N/A	N/A	50
CLYM Climb Bio	3.1915 of 5 stars	$10.91 +1.0%	$21.73 +99.2%	+846.3%	$618.44M	N/A	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TTRX) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Turn Therapeutics (TTRX) Competitors

TTRX vs. SLDB, OCS, AURA, CLYM, and ALLO

How does Turn Therapeutics compare to Solid Biosciences?

Summary

How does Turn Therapeutics compare to Oculis?

Summary

How does Turn Therapeutics compare to Aura Biosciences?

Summary

How does Turn Therapeutics compare to Climb Bio?

Summary

How does Turn Therapeutics compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Turn Therapeutics (TTRX) Competitors

TTRX vs. SLDB, OCS, AURA, CLYM, and ALLO

How does Turn Therapeutics compare to Solid Biosciences?

Does the media refer more to TTRX or SLDB?

Is TTRX or SLDB more profitable?

Which has higher valuation & earnings, TTRX or SLDB?

Do institutionals and insiders hold more shares of TTRX or SLDB?

Do analysts rate TTRX or SLDB?

Summary

How does Turn Therapeutics compare to Oculis?

Do analysts rate TTRX or OCS?

Which has better valuation and earnings, TTRX or OCS?

Do insiders and institutionals have more ownership in TTRX or OCS?

Is TTRX or OCS more profitable?

Does the media prefer TTRX or OCS?

Summary

How does Turn Therapeutics compare to Aura Biosciences?

Which has better valuation & earnings, AURA or TTRX?

Do insiders and institutionals hold more shares of AURA or TTRX?

Is AURA or TTRX more profitable?

Do analysts prefer AURA or TTRX?

Does the media refer more to AURA or TTRX?

Summary

How does Turn Therapeutics compare to Climb Bio?

Does the media favor TTRX or CLYM?

Do insiders and institutionals believe in TTRX or CLYM?

Is TTRX or CLYM more profitable?

Which has better earnings and valuation, TTRX or CLYM?

Do analysts recommend TTRX or CLYM?

Summary

How does Turn Therapeutics compare to Allogene Therapeutics?

Do institutionals and insiders hold more shares of ALLO or TTRX?

Does the media refer more to ALLO or TTRX?

Which has better valuation & earnings, ALLO or TTRX?

Is ALLO or TTRX more profitable?

Do analysts prefer ALLO or TTRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTRX vs. The Competition

Turn Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools